Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAH250
- Development stage
- Unknown
- Lead developer
- Essen Biotech
- Modality
- Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BAH250 is an investigational tumor-infiltrating lymphocyte (TIL) therapy being developed by Essen Biotech for the treatment of metastatic refractory stomach and esophageal cancer. As a personalized cellular immunotherapy, the production process involves isolating naturally occurring TILs—specifically CD8+ and CD4+ T cell subsets—from a patient's own tumor tissue. These cells are expanded ex vivo to billions of cells and then reinfused into the patient following a lymphodepleting conditioning regimen. Once reinfused, these autologous immune cells are designed to recognize and mediate a targeted anti-tumor response against cancer cells. BAH250 is currently in Phase 2 clinical development.
- Other names
- BAH250 TIL therapyBAH-250 TIL therapyBAH 250 TIL therapy
Beyond the preview
Go deeper on BAH250.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BAH250.